On Demand: Overcoming Cancer-Related Anemia with Intravenous Iron: Hematologist/Oncologist Approaches for Optimizing Clinical Outcomes & Improving Patient Quality of Life
This timely, adaptive, and dynamic educational activity is targeted to hematologists, oncologists, heme/onc residents/fellows, and the interprofessional hematology/oncology care team of nurse practitioners, physician assistants, pharmacists, and nurses. Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of cancer-related anemia (CRA) management, including chemotherapy-induced anemia (CIA). The session will begin with a thorough review of iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment approaches. An exhaustive appraisal of the etiology and foundational pathophysiology of CRA will follow, with a central emphasis on the role of hepcidin and functional iron deficiency (FID) in a hyperinflammatory disease state like cancer, and how those interlaced processes should lead to preferential use of intravenous (IV) iron versus oral iron modalities in patients with cancer. Completed, ongoing, and planned clinical trials of IV iron for CRA, both as monotherapy and as a component of combinatorial regimens, will be examined, and next generation formulations with nanocolloidal drug design will be highlighted, especially their substantively improved safety profiles over the older high-molecular weight (HMW) dextran products. Finally, using real-world patient cases, premier hematology/oncology experts will share insights on how and why IV iron possesses the capacity to revolutionize treatment of CRA and CIA, the importance of nanomedicine, budgetary impact analyses (BIA) of IV iron products, the natural history of IV iron agents to-date and the critical distinguishing factors among those currently-approved, and lastly, the provision of evidence-based algorithms for optimal diagnosis, evaluation, and safe, effective treatment of iron deficiency anemia in cancer.
Presented by Creative Educational Concepts.
Supported through an independent educational grant from American Regent.
Friday Satellite Symposium on Overcoming Cancer-Related Anemia with Intravenous Iron: Hematologist/Oncologist Approaches for Optimizing Clinical Outcomes & Improving Patient Quality of Life preceding the 63rd ASH Annual Meeting and Exposition.
Hematologists, oncologists, heme/onc residents/fellows, nurse practitioners, physician assistants, pharmacists, and nurses attending the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition who manage patients with cancer.
- Discuss the basic principles of iron metabolism and absorption, including the practical and pivotal distinctions between functional and absolute iron deficiency, with a focus on how these principles apply to treatment of patients with cancer.
- Understand the multifactorial etiologies and complex pathophysiology of iron deficiency anemia (IDA) in cancer, with an emphasis on functional IDA (FIDA), and evaluate the role of inflammation and hepcidin on iron supplementation strategies.
- Recognize the prevalence and robust clinical gravity of cancer-related anemia (CRA), including the deleterious impact on patient-reported quality-of-life metrics.
- Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices, alongside hemoglobin, for IDA in cancer, and implement the “diagnose, treat-to-target, and rapid reassessment cycle” into practice.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for CRA and chemotherapy-induced anemia (CIA), and identify how the innovative nanoparticle design of next-generation IV iron products dramatically improves upon the safety profiles of high-molecular weight (HMW) dextran agents.
- Explore what it means to circumvent “functional iron block” using IV iron therapies.
- Using real-world patient cases, interpolate the expanding evidentiary base regarding the impact of inflammation and hepcidin on iron availability and utilization, especially in a hyperinflammatory state like cancer, and the resultant rationale for preferential treatment with IV iron vs. oral iron, and effectively translate recent trial data into clinical practice.
- Examine budgetary impact analyses of IV iron products, highlighting the ameliorated clinical burden and cost savings associated with reduced hospitalizations, ESA dosage, and transfusion requirements, the relevance of nanomedicine, and distinguish the currently-approved IV iron agents, including the nuances that yield unique clinical utility.
Welcome and Introductions/Pre-test
Functional Iron Deficiency in Oncology: The Foundational Etiology and Pathophysiology of Cancer-Related Anemia
Mapping a New Landscape in Cancer-Related Anemia: Innovative Therapeutic Approaches with Intravenous Iron Products
Heme/Onc Expert Roundtable: Exploring the Clinical and Budgetary Implications of Using IV Iron Therapies in Cancer Care
Conversations with the Experts/Audience Q&A/Post-test
George M. Rodgers, MD, PhD
Professor of Medicine
Division of Hematology and Hematologic Malignancies
University of Utah School of Medicine and Huntsman Cancer Center
Salt Lake City, UT
George M. Rodgers, MD, PhD is a Professor of Medicine and Pathology at the University of Utah Health Sciences Center. He is also Medical Director of the Coagulation Laboratory at ARUP Laboratories. He received his M.D. and Ph.D degrees from Tulane University, did internal medicine training at Baylor College of Medicine, and received hematology fellowship training at UCSF.
Dr. Rodgers’ clinical research interests include diagnosis and treatment of iron deficiency and managing disorders of hemostasis and thrombosis. He has published over 250 journal articles and book chapters as well as 4 books. He was chair of the National Comprehensive Cancer Network (NCCN) Panel on Anemia for 14 years, and has been an associate editor of Wintrobe’s Clinical Hematology textbook for 23 years.
Michael Auerbach, MD, FACP
Auerbach Hematology and Oncology Associates, Inc.
Clinical Professor of Medicine
Georgetown University School of Medicine
Michael Auerbach, MD, FACP, is a hematologist/oncologist at Auerbach Hematology and Oncology Associates, Inc., in Baltimore, Maryland, and a Clinical Professor of Medicine at Georgetown University School of Medicine in Washington DC. Dr. Auerbach earned his medical degree from New York Medical College in Valhalla, New York. He completed his internship and residency in internal medicine at the Cleveland Clinic Foundation in Ohio. Subsequently, he completed his fellowship training in hematology and oncology at Columbia Presbyterian Medical Center and Harlem Hospital Center in New York, New York, where he went on to do a research fellowship in thrombosis and hemostasis at Columbia. He is board-certified in internal medicine and in the subspecialties of hematology and medical oncology.
Dr. Auerbach has authored or coauthored over 180 journal articles, books, chapters and meeting abstracts, most recently focusing on intravenous iron supplementation in pregnancy and in patients with RLS. He is an author of the Treatment of Iron Deficiency in Adults, Anemia in Pregnancy, and Diagnosis and Causes of Iron Deficiency for UpToDate. He is a member of numerous professional organizations, a Fellow of the American College of Physicians, and Honorary Emeritus member of the American Society of Hematology. He currently serves on the scientific board of the Network for Advancement of Transfusion Alternatives, advises the Society for the Advancement of Blood Management and is on the Editorial Boards of the American Journal of Hematology, Blood Transfusion and Expert Review of Hematology.
In 2010, along with three colleagues, he participated in the first educational session ever delivered on the use of intravenous iron, at the American Society of Hematology’s annual meeting and in 2016 presented another on complete replacement dosing in an initial, brief, single visit. In December, 2017 he was the principal author of the first prospective study of intravenous iron in pregnancy performed in the United States which was published in the American Journal of Medicine.
Thomas G. DeLoughery, MD, MACP, FAWM
Professor of Medicine
Oregon Health and Sciences University School of Medicine
OHSU Knight Cancer Institute
Tom DeLoughery (Dee-low-ree) is a native Hoosier who graduated from Indiana State University one year after Larry Bird and received his MD at Indiana University School of Medicine. He did his internship at the University of California, Irvine before traveling to Oregon where he finished his internal medicine residency and hematology/oncology fellowship at Oregon Health & Science University (OHSU). He is currently a Professor of Medicine, Pathology and Pediatrics in the Divisions of Hematology/Oncology and Laboratory Medicine at OHSU. His clinical interests are in iron deficiency, general hematology and coagulation. He was course director for the medical school Blood Course for ten years and has been awarded numerous teaching awards. He also has an interest in the hematologic aspects of Wilderness Medicine and served six years on the board of directors of the Wilderness Medicine Society and chaired their research committee for four years. He is a Master of the American College of Physicians and is a Fellow of the Academy of Wilderness Medicine.
Patricia A. Ford, MD
Clinical Professor of Medicine, Hematology/Oncology
University of Pennsylvania, Penn Medicine
Patricia A. Ford, MD, is a Clinical Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia. She is a member of the medical staff at Pennsylvania Hospital in the Division of Hematology/Oncology. Dr. Ford is the Medical Director of The Center for Transfusion Free Medicine at Pennsylvania Hospital, the Medical Director for the Autologous Transplant Program for which she performed the world’s first and largest series of transplants without blood product support for Jehovah Witnesses. She is also the Medical Director of the Clinical Research Unit East at Pennsylvania Hospital.
Dr. Ford received her medical degree at the University of Miami. Her postgraduate training included an internship and residency in medicine and a fellowship in Hematology/Oncology at Fox Chase Cancer Center. Dr. Ford is board certified in internal medicine and holds subspecialty certification in both hematology and oncology.
Dr. Ford is a founding member and past president of the Society for the Advancement of Blood Management. She is currently the co-chair of the Annual Planning Committee for the SABM Annual Meeting. Dr. Ford is currently a member of the American Society of Clinical Oncology and American Society of Hematology. Her areas of interest are diagnosis and treatment of anemia, iron deficiency especially for at risk women. She is also interested in patient blood management and alternatives to transfusion support.
John A. Glaspy, MD, MPH
Professor of Medicine
Hematology and Oncology
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, CA
John Glaspy, MD, MPH, is professor of medicine at the Jonsson Comprehensive Cancer Center (JCCC) of the University of California, Los Angeles (UCLA) School of Medicine. Dr. Glaspy holds the Simms /Mann Family Foundation Chair in Integrative Oncology. He previously held the Estelle, Abe, and Marjorie Sanders Endowed Chair in Cancer Research.
Dr. Glaspy is a member of the American Society of Clinical Oncology, Southwest Oncology Group, American Federation for Clinical Research, International Society of Interferon Research, and American Society of Nuclear Medicine, among others. He is also a fellow of the American College of Physicians. During the course of his career, Dr. Glaspy has authored more than 400 articles, abstracts, and book chapters. He has received numerous awards and honors, including being named one of the “Best Doctors in America.” Dr. Glaspy, has been involved in the design and founding of Stand Up to Cancer, an organization that has raised 120 million dollars for cancer research to date. He has also, been involved with this organization from the beginning three years ago and continue to serve as the Chair of its Management Committee.
Currently, Dr. Glaspy is involved in clinical trials of therapies for melanoma and breast cancer as well as supportive care trials. He is also involved in health services research exploring quality of care improvement and financial toxicity for patients.
Dr. Glaspy received his MD from the UCLA School of Medicine and his MPH in health services administration from the UCLA School of Public Health. He completed his residency in internal medicine and his fellowship in hematology and oncology at the UCLA School of Medicine.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
George M. Rodgers, MD, PhD–has disclosed that he is a consultant for Pharmacosmos.
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Michael Auerbach, MD, FACP–has disclosed that he receives grant/research support from Covis Pharmaceuticals and Pharmacosmos.
Thomas G. DeLoughery, MD, MACP, FAWM–has no relevant financial relationships to disclose in relation to the content of this activity.
Patricia A. Ford, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
John A. Glaspy, MD, MPH–has disclosed that he is s a consultant for AMAG. He receives grant/research support from Fibrogen. He is on the speakers' bureau for AMAG.
George M. Rodgers, MD, PhD–has disclosed that he is a consultant for Pharmacosmos.
David H. Henry, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jillian L. McInerney, CRNP, MSN–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 3.0 contact hours.
Upon completion of a CE request form, statements of credit for physicians, and nurses will be issued within 30 days.
- 3.00 AMA PRA Category 1 Credit™
- 3.00 ANCC
- 3.00 Participation